Gilead Sciences raises 2026 outlook significantly. The pharmaceutical company projects Yeztugo sales will reach $1 billion next year, demonstrating strong market demand for its newer therapies. Gilead lifted its full-year revenue guidance to $29.4 billion to $29.8 billion, reflecting confidence in both established and emerging products. HIV sales grew 10 percent, underscoring the company's continued dominance in this therapeutic area. The guidance increase signals successful drug launches and sustained market penetration across its portfolio. Investors should monitor upcoming FDA catalysts that could further drive growth. Gilead's performance reflects broader strength in the pharmaceutical sector and validates its strategic focus on high-value treatments.
Post from MarketNews_en
Log in to interact with content.